Anti-hbs monoclonal antibodies
A monoclonal antibody and antibody technology, applied in the direction of anti-animal/human immunoglobulin, cells modified by introducing foreign genetic material, biochemical equipment and methods, etc., can solve the problems of infection transmission, affecting HBV hosts, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
experiment example 1
[0090] (1) Preparation of monoclonal antibodies
[0091] 1-1. Immunization of mice
[0092] 100 μl of FCA was added to 100 μl of PBS containing 50 μg of inactivated adr-type HBsAg (manufactured by TRINA) purified from human serum, and mixed and emulsified with a Voltex vortex to prepare 200 μl of an FCA-mixed HBsAg solution. In addition, 200 µl of an FIA-mixed HBsAg solution was prepared in the same manner except that FIA was used instead of FCA.
[0093] Primary immunization was performed by injecting 200 μl of FCA mixed with HBsAg solution into the abdominal cavity of 8-week-old female BALB / c mice. After the initial immunization, 200 μl of FIA mixed HBsAg solution was used for five booster immunizations every two weeks. Four days after the last booster immunization, splenocytes were isolated, and the cells were fused with P3X63-Ag8·653 mouse myeloma cells using the PEG method to prepare hybridomas.
[0094] 1-2. Culture of hybridoma
[0095] Suspend the hybridomas in HT ...
experiment example 2
[0108] Using DNA of wild-type HBsAg as a template, DNA encoding the amino acid sequence from position 1 to position 196 of wild-type HBsAg (subtype: adr) was prepared by PCR method and inserted into the expression vector pcDNA3.1(+) for eukaryotic cells , A plasmid for expressing wild-type HBsAg was prepared. Introduce the plasmid into COS7 cells, in 5% CO 2 Incubate in an incubator for 24 hours. The COS7 cells can express HBsAg with amino acid deletion below 197 (hereinafter referred to as C-terminal deletion HBsAg).
[0109] Whether or not the 149 antibody and the 1053 antibody react with the C-terminal-deleted HBsAg was determined in the same manner as in Experimental Example 1. The judgment results are shown in Table 3 below.
[0110] Antibody 149
[0111] From Table 3, it can be confirmed that the 149 antibody and the 1053 antibody can recognize the C-terminal deletion HBsAg. From this, it was found that the epitopes of the 149 antibody and the 1053 antibo...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com